© 2020 MJH Life Sciences and Urology Times. All rights reserved.
Bladder Cancer
Gene-mediated therapy for high-grade NMIBC delivers positive results in trial
July 14, 2020
72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.
Cabozantinib shows intriguing activity in heavily pretreated urothelial carcinoma
July 08, 2020
Cabozantinib's single-agent activity opens the potential for combination approaches with immunotherapy in patients with heavily pretreated urothelial carcinoma.
How to perform office-based blue light cystoscopy
July 07, 2020
BLC with hexaminolevulinate can be an easily replicable procedure in patients with non–muscle-invasive bladder cancer.
Speaking of Urology podcast: Dr. Angela Smith discusses Jelmyto for low-grade UTUC
July 06, 2020
In this episode, Angela B. Smith, MD, MS, of UNC Lineberger Comprehensive Cancer Center, discusses the recent FDA approval of Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer.
FDA approves avelumab as frontline maintenance in urothelial carcinoma
July 01, 2020
The FDA has approved the PD-L1 inhibitor avelumab for the frontline maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.
Personalized cancer vaccine combo induces clinical benefit in advanced solid tumors
June 22, 2020
The combination of the personalized cancer vaccine RO719845 and the PD-L1 inhibitor atezolizumab showed strong clinical activity across solid tumors, including bladder cancer and renal cell carcinoma.
Atezolizumab shows similar efficacy in upper tract urothelial carcinoma and standard bladder cancer
June 19, 2020
Median overall survival is the same for both malignancies, study results show.
Biomarker combo forecasts improved survival with anti–PD-1/L1 agents in bladder cancer
June 18, 2020
The dual biomarker of ARID1A mutations and CXCL13 expression was associated with improved overall survival in patients with advanced urothelial carcinoma.
Immune checkpoint inhibitors effective in variant urothelial carcinoma
June 17, 2020
Anti–PD-1/PD-L1 agents were associated with similar efficacy across pure and variant histologies in patients with advanced urothelial carcinoma, with the exception of those with a neuroendocrine variant.
FDA approves pembrolizumab across TMB-high solid tumors
June 17, 2020
Pembrolizumab has been granted a second tumor-agnostic FDA indication, this one for patients with solid tumors with a high tumor mutational burden.